fasudil has been researched along with Left Ventricular Dysfunction in 6 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with fasudil at a dose of 30 mg/kg/day from days 1 to 28 or from days 29 to 42 decreased the mean pulmonary arterial pressure by 57% and 56%, right ventricular hypertrophy by 31% and 30%, pulmonary arteriolar medial thickness by 50% and 50%, and pulmonary expression of Rho-kinase II by 41% and 28%, respectively, as well as augmented pulmonary expression of eNOS by 16% and 31% and NO by 50% and 76%, respectively, when compared with the vehicle controls." | 5.37 | Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. ( Chai, CY; Chen, IC; Chen, IJ; Chou, SH; Dai, ZK; Tan, MS; Wu, BN; Wu, JR; Yeh, JL, 2011) |
| "Treatment with fasudil, a ROCK inhibitor, significantly protected against diabetes-induced myocardial hypertrophy, fibrosis and mitochondrial dysfunction." | 1.91 | Speckle-tracking echocardiography provides sensitive measurements of subtle early alterations associated with cardiac dysfunction in T2DM rats. ( Chen, Z; Guo, B; Li, Y; Liu, G; Liu, S; Liu, Z; Ma, M; Qi, Y; Wang, L; Xue, L; Yin, Y, 2023) |
| "Treatment with fasudil at a dose of 30 mg/kg/day from days 1 to 28 or from days 29 to 42 decreased the mean pulmonary arterial pressure by 57% and 56%, right ventricular hypertrophy by 31% and 30%, pulmonary arteriolar medial thickness by 50% and 50%, and pulmonary expression of Rho-kinase II by 41% and 28%, respectively, as well as augmented pulmonary expression of eNOS by 16% and 31% and NO by 50% and 76%, respectively, when compared with the vehicle controls." | 1.37 | Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. ( Chai, CY; Chen, IC; Chen, IJ; Chou, SH; Dai, ZK; Tan, MS; Wu, BN; Wu, JR; Yeh, JL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Qi, Y | 1 |
| Chen, Z | 1 |
| Guo, B | 1 |
| Liu, Z | 1 |
| Wang, L | 1 |
| Liu, S | 1 |
| Xue, L | 1 |
| Ma, M | 1 |
| Yin, Y | 1 |
| Li, Y | 1 |
| Liu, G | 1 |
| Guo, R | 1 |
| Su, Y | 1 |
| Yan, J | 1 |
| Sun, H | 1 |
| Wu, J | 1 |
| Liu, W | 1 |
| Xu, Y | 1 |
| Waddingham, MT | 1 |
| Edgley, AJ | 1 |
| Astolfo, A | 1 |
| Inagaki, T | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Tsuchimochi, H | 1 |
| Yagi, N | 1 |
| Kelly, DJ | 1 |
| Shirai, M | 1 |
| Pearson, JT | 1 |
| Mera, C | 1 |
| Godoy, I | 1 |
| RamÃrez, R | 1 |
| Moya, J | 1 |
| Ocaranza, MP | 1 |
| Jalil, JE | 1 |
| Dai, ZK | 1 |
| Wu, BN | 1 |
| Chen, IC | 1 |
| Chai, CY | 1 |
| Wu, JR | 1 |
| Chou, SH | 1 |
| Yeh, JL | 1 |
| Chen, IJ | 1 |
| Tan, MS | 1 |
| Hattori, T | 1 |
| Shimokawa, H | 1 |
| Higashi, M | 1 |
| Hiroki, J | 1 |
| Mukai, Y | 1 |
| Tsutsui, H | 1 |
| Kaibuchi, K | 1 |
| Takeshita, A | 1 |
1 trial available for fasudil and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Fasudil improves short-term echocardiographic parameters of diastolic function in patients with type 2 diabetes with preserved left ventricular ejection fraction: a pilot study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Diabetes Mellitus, Type 2; Diastole; Echocardio | 2015 |
5 other studies available for fasudil and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Speckle-tracking echocardiography provides sensitive measurements of subtle early alterations associated with cardiac dysfunction in T2DM rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Echocardiography; Rats; Ventricular D | 2023 |
Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Diabetes Mellitus, Experimental; Dia | 2015 |
Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Extracellular Signal | 2016 |
Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Cyclic GMP; Endothelin-1; Hypert | 2011 |
Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; DNA-Binding Proteins; Drug Administration Sc | 2004 |